Multivariable survival analyses by IBMFS-associated variant status categories
| . | n Death/Total . | All-cause Mortality . | ||
|---|---|---|---|---|
| All patients | HR* (95% CI) | P | ||
| 26/48 | Unrecognized IBMFS | 2.13 (1.40-3.24) | .0004 | |
| 22/72 | Carrier | 0.96 (0.62-1.50) | .86 | |
| 205/606 | No variant | Reference | ||
| Unrelated donor | HR* (95% CI) | P | ||
| 26/41 | Unrecognized IBMFS | 2.20 (1.44-3.35) | .0003 | |
| 22/64 | Carrier | 1.01 (0.65-1.58) | .97 | |
| 197/527 | No variant | Reference | ||
| Myeloablative | HR† (95% CI) | P | ||
| 16/21 | Unrecognized IBMFS | 2.05 (1.18-3.56) | .01 | |
| 16/29 | Carrier | 1.36 (0.79-2.36) | .27 | |
| 108/228 | No variant | Reference | ||
| Reduced-intensity/nonmyeloablative | HR† (95% CI) | P | ||
| 10/27 | Unrecognized IBMFS | 2.39 (1.21-4.69) | .01 | |
| 6/43 | Carrier | 0.60 (0.26-1.40) | .24 | |
| 96/374 | No variant | Reference | ||
| DNA damage response | HR* (95% CI) | P | ||
| 4/6 | Unrecognized IBMFS | 4.43 (1.56-12.62) | .0053 | |
| 12/41 | Carrier | 0.84 (0.47-1.52) | .57 | |
| 205/606 | No variant | Reference | ||
| Hematopoiesis | HR* (95% CI) | P | ||
| 8/21 | Unrecognized IBMFS | 1.31 (0.64-2.70) | .46 | |
| 2/11 | Carrier | 0.59 (0.14-2.42) | .46 | |
| 205/606 | No variant | Reference | ||
| Ribosome biology | HR* (95% CI) | P | ||
| 3/6 | Unrecognized IBMFS | 2.22 (0.69-7.12) | .18 | |
| 3/9 | Carrier | 1.17 (0.37-3.76) | .79 | |
| 205/606 | No variant | Reference | ||
| Telomere biology | HR* (95% CI) | P | ||
| 11/15 | Unrecognized IBMFS | 2.84 (1.49-5.42) | .0015 | |
| 5/11 | Carrier | 1.87 (0.76-4.60) | .18 | |
| 205/606 | No variant | Reference | ||
| . | n Death/Total . | All-cause Mortality . | ||
|---|---|---|---|---|
| All patients | HR* (95% CI) | P | ||
| 26/48 | Unrecognized IBMFS | 2.13 (1.40-3.24) | .0004 | |
| 22/72 | Carrier | 0.96 (0.62-1.50) | .86 | |
| 205/606 | No variant | Reference | ||
| Unrelated donor | HR* (95% CI) | P | ||
| 26/41 | Unrecognized IBMFS | 2.20 (1.44-3.35) | .0003 | |
| 22/64 | Carrier | 1.01 (0.65-1.58) | .97 | |
| 197/527 | No variant | Reference | ||
| Myeloablative | HR† (95% CI) | P | ||
| 16/21 | Unrecognized IBMFS | 2.05 (1.18-3.56) | .01 | |
| 16/29 | Carrier | 1.36 (0.79-2.36) | .27 | |
| 108/228 | No variant | Reference | ||
| Reduced-intensity/nonmyeloablative | HR† (95% CI) | P | ||
| 10/27 | Unrecognized IBMFS | 2.39 (1.21-4.69) | .01 | |
| 6/43 | Carrier | 0.60 (0.26-1.40) | .24 | |
| 96/374 | No variant | Reference | ||
| DNA damage response | HR* (95% CI) | P | ||
| 4/6 | Unrecognized IBMFS | 4.43 (1.56-12.62) | .0053 | |
| 12/41 | Carrier | 0.84 (0.47-1.52) | .57 | |
| 205/606 | No variant | Reference | ||
| Hematopoiesis | HR* (95% CI) | P | ||
| 8/21 | Unrecognized IBMFS | 1.31 (0.64-2.70) | .46 | |
| 2/11 | Carrier | 0.59 (0.14-2.42) | .46 | |
| 205/606 | No variant | Reference | ||
| Ribosome biology | HR* (95% CI) | P | ||
| 3/6 | Unrecognized IBMFS | 2.22 (0.69-7.12) | .18 | |
| 3/9 | Carrier | 1.17 (0.37-3.76) | .79 | |
| 205/606 | No variant | Reference | ||
| Telomere biology | HR* (95% CI) | P | ||
| 11/15 | Unrecognized IBMFS | 2.84 (1.49-5.42) | .0015 | |
| 5/11 | Carrier | 1.87 (0.76-4.60) | .18 | |
| 205/606 | No variant | Reference | ||
Models were adjusted for recipient age, HLA matching, recipient race, conditioning intensity, donor age, Karnofsky Performance Score, and recipient sex and stratified on the year of transplant and donor type.
Models were adjusted for recipient age, recipient race, donor age, Karnofsky Performance Score, conditioning regimen, and recipient sex and stratified on the year of transplant and donor type.